US Patent

US11872192 — RET inhibitor for use in treating cancer having a RET alteration

Method of Use · Assigned to Blueprint Medicines Corp · Expires 2039-04-03 · 13y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating cancer with a RET alteration by administering a selective RET inhibitor, such as Compound 1, in a daily dose of 60-400 mg.

USPTO Abstract

Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.

Drugs covered by this patent

Gavreto (PRALSETINIB) · Rigel Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2952`	—	Gavreto

Patent Metadata

Patent number: US11872192
Jurisdiction: US
Classification: Method of Use
Expires: 2039-04-03
Drug substance claim: No
Drug product claim: No
Assignee: Blueprint Medicines Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.